Inhibition of Lymphoma Cell Proliferation by Peroxisomal Proliferator-Activated Receptor-γ Ligands via Wnt Signaling Pathway

Cell Biochemistry and Biophysics

Volumn 62, Issue 1, 2012, Pages 19-27

  Liu, Jia Jun ^a   Dai, Xue Jun ^b   Xu, Yan ^a   Liu, Pei Qing ^c   Zhang, Yong ^a   Liu, Xiao Dan ^a   Fang, Zhi Gang ^a   Lin, Dong Jun ^a   Xiao, Ruo Zhi ^a   Huang, Ren Wei ^a   Huang, He Qing ^c  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Catenin; Apoptosis; Cell cycle; GW9662; PPAR ; Rosiglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTINEOPLASTIC AGENT; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; LYMPHOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LIGANDS; LYMPHOMA; PHOSPHORYLATION; PPAR GAMMA; THIAZOLIDINEDIONES; WNT SIGNALING PATHWAY;

EID: 84855579880     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9253-x     Document Type: Article

References (41)

1. Blum, K. A., Lozanski, G., & Byrd, J. C. (2004). Adult Burkitt leukemia and lymphoma. Blood, 104, 3009-3020.
2. Issemann, I., & Green, S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 347, 645-650.
3. Bocher, V., Chinetti, G., Fruchart, J. C., & Staels, B. (2002). Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control. Journal of Social Biology, 196, 47-52.
4. Ulivieri, C., & Baldari, C. T. (2007). The potential of peroxisome proliferator-activated receptor gamma (PPARgamma) ligands in the treatment of hematological malignancies. Mini Reviews in Medicinal Chemistry, 7, 877-887.
5. Wang, T., Xu, J., Yu, X., Yang, R., & Han, Z. C. (2006). Peroxisome proliferator-activated receptor gamma in malignant diseases. Critical Reviews in Oncology/Hematology, 58, 1-14.
6. Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000). The PPARs: From orphan receptors to drug discovery. Journal of Medicinal Chemistry, 43, 527-550.
7. Konopleva, M., Elstner, E., McQueen, T. J., Tsao, T., Sudarikov, A., et al. (2004). Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Molecular Cancer Therapeutics, 3, 1249-1262.
8. Liu, H., Zang, C., Fenner, M. H., Liu, D., Possinger, K., et al. (2006). Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood, 107, 3683-3692.
9. Ray, D. M., Akbiyik, F., & Phipps, R. P. (2006). The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12, 14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. Journal of Immunology, 177, 5068-5076.
10. Tabe, Y., Konopleva, M., Kondo, Y., Contractor, R., Tsao, T., et al. (2007). PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biology & Therapy, 6, 1967-1977.
11. Read, W. L., Baggstrom, M. Q., Fracasso, P. M., & Govindan, R. (2008). A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. Chemotherapy, 54, 236-241.
12. Rieger, M. E., Sims, A. H., Coats, E. R., Clarke, R. B., & Briegel, K. J. (2010). The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers. Molecular and Cellular Biology, 30, 4267-4279.
13. Liu, X., Rubin, J. S., & Kimmel, A. R. (2005). Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins. Current Biology, 15, 1989-1997.
14. Takahashi-Yanaga, F., & Sasaguri, T. (2009). Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: Inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. J Pharmacol Sci, 109, 179-183.
15. Meijer, L., Flajolet, M., & Greengard, P. (2004). Pharmacological inhibitors of glycogen synthase kinase 3. Trends in Pharmacological Sciences, 25, 471-480.
16. McNeill, H., & Woodgett, J. R. (2010). When pathways collide: Collaboration and connivance among signalling proteins in development. Nature Reviews Molecular Cell Biology, 11, 404-413.
17. Sopko, R., Silva, E., Clayton, L., Gardano, L., Barrios-Rodiles, M., et al. (2009). Phosphorylation of the tumor suppressor fat is regulated by its ligand Dachsous and the kinase discs overgrown. Current Biology, 19, 1112-1117.
18. Silva, E., Tsatskis, Y., Gardano, L., Tapon, N., & McNeill, H. (2006). The tumor-suppressor gene fat controls tissue growth upstream of expanded in the hippo signaling pathway. Current Biology, 16, 2081-2089.
19. Herbst, A., & Kolligs, F. T. (2007). Wnt signaling as a therapeutic target for cancer. Methods in Molecular Biology, 361, 63-91.
20. Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., et al. (2003). A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature, 423, 409-414.
21. Roman-Gomez, J., Cordeu, L., Agirre, X., Jimenez-Velasco, A., San Jose-Eneriz, E., et al. (2007). Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood, 109, 3462-3469.
22. Chim, C. S., Pang, R., Fung, T. K., Choi, C. L., & Liang, R. (2007). Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia, 21, 2527-2536.
23. Fujisawa, T., Nakajima, A., Fujisawa, N., Takahashi, H., Ikeda, I., et al. (2008). Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathway. Journal of Pharmacological Sciences, 106, 627-638.
24. Seargent, J. M., Yates, E. A., & Gill, J. H. (2004). GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. British Journal of Pharmacology, 143, 933-937.
25. Burton, J. D., Castillo, M. E., Goldenberg, D. M., & Blumenthal, R. D. (2007). Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines. Anticancer Drugs, 18, 525-534.
26. Jarrar, M. H., & Baranova, A. (2007). PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: The importance of interplay with TGFbeta signalling. J Cell Mol Med, 11, 71-87.
27. Konturek, P. C., Kania, J., Konturek, J. W., Nikiforuk, A., Konturek, S. J., et al. (2003). H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR gamma and impaired apoptosis in gastric carcinogenesis. Medical Science Monitor, 9, SR53-SR66.
28. Thompson, E. A. (2007). PPARgamma physiology and pathology in gastrointestinal epithelial cells. Molecules and Cells, 24, 167-176.
29. Eberhardt, N. L., Grebe, S. K., McIver, B., & Reddi, H. V. (2010). The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Molecular and Cellular Endocrinology, 321, 50-56.
30. Wahli, W. (2008). A gut feeling of the PXR, PPAR and NF-kappaB connection. Journal of Internal Medicine, 263, 613-619.
31. Zhang, X., & Young, H. A. (2002). PPAR and immune system-what do we know? International Immunopharmacology, 2, 1029-1044.
32. Ondrey, F. (2009). Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: Implications for chemoprevention. Clinical Cancer Research, 15, 2-8.
33. Chen, Y. C., Shen, S. C., & Tsai, S. H. (2005). Prostaglandin D(2) and J(2) induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochimica et Biophysica Acta, 1743, 291-304.
34. Konopleva, M., Tsao, T., Estrov, Z., Lee, R. M., Wang, R. Y., et al. (2004). The synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Research, 64, 7927-7935.
35. Liu, J. J., Huang, R. W., Lin, D. J., Peng, J., Wu, X. Y., et al. (2005). Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Annals of Oncology, 16, 455-459.
36. Liu, J., Lu, H., Huang, R., Lin, D., Wu, X., et al. (2005). Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemotherapy and Pharmacology, 56, 400-408.
37. Bertram, J. S., & Vine, A. L. (2005). Cancer prevention by retinoids and carotenoids: Independent action on a common target. Biochimica et Biophysica Acta, 1740, 170-178.
38. Zand, H., Rahimipour, A., Salimi, S., & Shafiee, S. M. (2008). Docosahexaenoic acid sensitizes Ramos cells to Gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-kappaB suppression. Molecular and Cellular Biochemistry, 317, 113-120.
39. Lu, D., & Carson, D. A. (2010). Repression of beta-catenin signaling by PPAR gamma ligands. European Journal of Pharmacology, 636, 198-202.
40. Deshpande, A. J., & Buske, C. (2007). Knocking the Wnt out of the sails of leukemia stem cell development. Cell Stem Cell, 1, 597-598.
41. Gerhold, D. L., Liu, F., Jiang, G., Li, Z., Xu, J., et al. (2002). Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology, 143, 2106-2118.